PMID- 32676895
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Linking)
VI  - 23
IP  - 3
DP  - 2021 Mar
TI  - Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in 
      patients with colon cancer: a latent class analysis.
PG  - 657-662
LID - 10.1007/s12094-020-02454-z [doi]
AB  - OBJECTIVE: To identify distinct trajectories of toxicity in colorectal cancer 
      (CRC) patients after adjuvant chemotherapy and its impact on quality of life 
      (QoL) and psychological symptoms. METHODS: A prospective, multicenter study was 
      conducted in 157 patients. A latent class analysis defined the unobserved latent 
      constructs that can be predicted as symptom clusters, considering the intensity 
      of four types of adverse events (AEs). Patients completed EORTC-QLQ-C30, BSI-18, 
      PDRQ-9, and DRS scales. RESULTS: Ninety-six percent had some degree of toxicity, 
      with grades 3-4 being the most common: neurotoxicity (7.2%), hematological 
      (13.1%), digestive (5.2%), and skin toxicity (1.4%). Three distinct latent 
      classes were identified (high [72.5%], mild [16.9%], and low [10.6%] toxicity). 
      Patients with high toxicity had the worst QoL scores and moderately high 
      somatization and psychological distress scores. CONCLUSIONS: Adjuvant 
      chemotherapy for CRC was associated with frequent toxicity that negatively 
      impacted QoL and psychological wellbeing.
FAU - Gomez, D
AU  - Gomez D
AD  - Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, 
      University of Pais Vasco, Pais Vasco, Avenida Roma sn, 33011, Oviedo, Spain.
FAU - Calderon, C
AU  - Calderon C
AD  - Department of Clinical Psychology and Psychobiology, Faculty of Psychology, 
      University of Barcelona, University of Pais Vasco, Pais Vasco, Barcelona, Spain.
FAU - Carmona-Bayonas, A
AU  - Carmona-Bayonas A
AD  - Department of Medical Oncology, Hospital Universitario Morales Meseguer, UMU, 
      IMI, Murcia, Spain.
FAU - Cacho Lavin, D
AU  - Cacho Lavin D
AD  - Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, 
      IDIVAL, Santander, Spain.
FAU - Munoz, M M
AU  - Munoz MM
AD  - Department of Medical Oncology, Hospital Universitario Virgen de La Luz, Cuenca, 
      Spain.
FAU - Martinez Cabanez, R
AU  - Martinez Cabanez R
AD  - Department of Medical Oncology, Hospital Universitario Fundacion Alcorcon, 
      Madrid, Spain.
FAU - Jimenez-Fonseca, P
AU  - Jimenez-Fonseca P
AUID- ORCID: 0000-0003-4592-3813
AD  - Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, 
      University of Pais Vasco, Pais Vasco, Avenida Roma sn, 33011, Oviedo, Spain. 
      palucaji@hotmail.com.
LA  - eng
GR  - FSEOM-Onvida for Projects on Long Survivors and Quality of Life. SEOM (Spanish 
      Society of Medical Oncology) 2015/Sociedad Espanola de Oncologia Medica/
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200716
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Organoplatinum Compounds)
RN  - 0 (Pyridines)
RN  - 0 (oxiplatin)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - Folfox protocol
SB  - IM
MH  - Aged
MH  - Antimetabolites, Antineoplastic/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Capecitabine/adverse effects
MH  - Chemotherapy, Adjuvant/adverse effects
MH  - Colonic Neoplasms/*drug therapy/mortality/pathology/*psychology
MH  - Decision Making
MH  - Emotions
MH  - Female
MH  - Fluorouracil/adverse effects
MH  - Humans
MH  - *Latent Class Analysis
MH  - Leucovorin/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Organoplatinum Compounds/adverse effects
MH  - Physician-Patient Relations
MH  - Prospective Studies
MH  - Pyridines/adverse effects
MH  - *Quality of Life
MH  - Spain
OTO - NOTNLM
OT  - Adjuvant treatment
OT  - Cancer
OT  - Latent class analysis
OT  - Oxaliplatin
OT  - Toxicity
OT  - Trajectory analysis
EDAT- 2020/07/18 06:00
MHDA- 2021/09/15 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
AID - 10.1007/s12094-020-02454-z [pii]
AID - 10.1007/s12094-020-02454-z [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2021 Mar;23(3):657-662. doi: 10.1007/s12094-020-02454-z. Epub 
      2020 Jul 16.